GCT’s core staff and top-management have Neurology and Psychiatry 20+ years background of managing 40+ trials in the U.S. and throughout Europe. It helps us maintain strong and solid relationships within clinical research community with KOLs and high-recruiting investigative sites in Russia and Eastern Europe.

The quality of clinical research data is proven by the percentage of FDA/EMA approved drugs studied within international clinical trials placed partially in Russia is increasing (from 21% in 2012 to 62% in 2015). In the EMA 2013 report, Russia stays among 5 top-enrolling countries in clinical research worldwide.

Central-Eastern Europe has recently reported an altered pattern in digestive system diseases: while the rise in quality of life has reduced infectious diseases rates, the prevalence of autoimmune diseases has in turn increased – such as Inflammatory Bowel Disease, considered to be a major burden in developed countries. Taking into account the trajectory of morbidity of digestive diseases, the development of new drugs and therapies for treatment is becoming more and more vital.

Oncology is the second most important cause of mortality in the Eastern European Region, contributing to 11% of the disease burden and around 20% of all deaths. Reported raising cancer incidence stipulates the expansion of clinical trials in the area and currently Russia and Central-Eastern European region are regarded by global pharmaceutical companies to be most important strategic locations for clinical research.

According to the WHO, just around 445 clinical trials of cancer are in progress in Russia, Ukraine, Romania, and Bulgaria annually, therefore these countries still have a lot of unfulfilled recruitment potential. Just Russia by itself has more than 50 cancer centers which run domestic and international clinical trials and can be rightfully considered a primary destination for oncology research.

Clinical trials in patients with eye diseases constitute an important part of GCT experience. Close ties to the corresponding community in the region has led us to being an exclusive informational partner for the annual “White Nights” ophthalmology congress, a leading event for more than 2000 local and international ophthalmology professionals. The event provides our team with a unique access to the database of potential investigators, gives an opportunity to stay on top of the industry research trends and maintain relations with the regional KOLs.

Each year more and more attention is drawn to the modern world’s unmet medical needs, many of which represent the field of orphan diseases. Guided by scientific progress and regulatory incentives, biopharmaceutical industry has increased their input to the complex process of orphan drug development.
The most obvious challenge for rare diseases clinical research is the small number of patients available in each indication. A typical orphan drug trial includes multiple sites worldwide, often with just a few patients enrolled at each location. CEE countries and Russia together come close to 300 million people population, making it a geographic area that cannot be ignored within this type of clinical trials.

Such medical conditions as ovarian cancer, endometriosis, inflammatory diseases, arterial hypertension, and many others affect women's reproductive health, particularly during pregnancy and childbirth. While it is highly essential to develop new drugs and diagnostics in reproductive endocrinology and infertility, the major players who reached the clinical development stage are facing a number of problems, including ethical issues, lack of experienced investigators and equipped sites.

According to EMA "Cooperation in the field of clinical trials" report, Russia is one of the top-enrolling countries in clinical research worldwide, whereas the quality of data coming from Russia and CEE region compared to Western Europe and US is quite high based on the statistics of recent FDA inspections. Those facts make our region an attractive destination to place clinical studies, especially in the sensitive area of male and female reproductive health.

For more than 15 years GCT has been gaining experience in multiple therapeutic areas to respond the needs of our Sponsors.

We are proud to be established as a CRO of choice by many KOLs and leading medical institutions in various therapeutic areas.